TITIN ANTIBODIES IN PATIENTS WITH LATE-ONSET MYASTHENIA-GRAVIS - CLINICAL CORRELATIONS

被引：67

作者：

SKEIE, GO

MYGLAND, A

AARLI, JA

GILHUS, NE

机构：

[1] Department of Neurology, University of Bergen, Bergen

来源：

AUTOIMMUNITY | 1995年 / 20卷 / 02期

关键词：

MYASTHENIA GRAVIS; THYMUS; TITIN ANTIBODIES;

D O I：

10.3109/08916939509001933

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We have tested sera from 21 thymectomized patients with onset of MG after 40 years of age and without thymoma for antibodies against titin, using ELISA with the titin peptide MGT-30. Titin is a myofibrillar protein unique to striated muscle and important for the elastic recoil of muscle cells. Titin antibodies were detected in 9 of the 21 sera. MG symptoms as assessed by a 6 point disability score (0-5) were significantly more severe in the titin antibody positive patients both at peak of illness; 3.7 vs. 3.1 (p < 0.02) and at latest follow up; 2.1 vs. 0.8 (p < 0.01). All titin antibody positive patients were on immunosuppressive drug treatment at least follow-up, whereas only 3 of 12 patients without titin antibodies used immunosuppressive drugs. The presence of circulating titin antibodies in late-onset non-thymoma MG patients indicates a more severe disease.

引用

页码：99 / 104

页数：6

共 32 条

[1]

Lindstrom J., Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome, Ann. Rev. Immunol., 3, pp. 109-131, (1985)

[2]

Lindstrom J.M., Seybold M.E., Lcnnon V.A., Whittingham S., Duane D.D., Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates and diagostic value, Neurology, 26, pp. 1054-1059, (1976)

[3]

Lefvert A.K., Bergstram K., Matell G., Osterman P.O., Pirskanen R., Determination f acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications, J. Neurol. Neurosurg. Psychiat., 41, pp. 394-403, (1978)

[4]

Oosterhuis H. J.G.H., Limburg P.C., Hummel-Tappel E., Anti-acctylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients, J. Neurol. Sci., 58, pp. 371-785, (1983)

[5]

Oosterhuis H. J.G.H., Myasthenia gravis, Clinical Neurology and Neurosurgery Monographs., (1984)

[6]

Pescarmona E., Rosati S., Pisacane A., Rendina E.A., Vcnuta F., Baroni C.D., Microscopic thymoma: histological evidence of multifocal cortical and medullary origin, Histopathology, 20, pp. 263-266, (1992)

[7]

Compston D.A.S., Vincent A., Newsom-Davis J., Batchclor J.R., Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis, Brain, 103, pp. 579-601, (1980)

[8]

Williams C.L., Lennon V.A., Thymic B-lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, a-actinin or actin, J. Exp. Med., 164, pp. 1043-1059, (1986)

[9]

Aarli J.A., Stefansson K., Marton L.S.G., Wollman R.L., Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin, Clin. Exp. Immunol., 82, pp. 284-288, (1990)

[10]

Ohta M., Ohta K., Itoh N., Et al., Anti-skeletal muscle antibodies in the sera from myasthenic patients with thymoma: identification of anti-myosin, actomyosin, actin and a-actinin antibodies by a solid-phase radioimmunoassay and a Western blotting analysis, Clin. Chim. Acta., 187, pp. 255-264, (1990)

← 1 2 3 4 →